Body Contouring in Houston

Overview

Body contouring: fat, muscle, skin, and cellulite

Body contouring covers several different problems: fat, muscle tone, loose skin, cellulite, and excess skin after weight loss. Each treatment is FDA-cleared or approved for specific uses, and none covers all of them. CoolSculpting and SculpSure are cleared to break down fat in listed body areas (FDA 510(k) K233732) (FDA 510(k) K182741). Emsculpt Neo is cleared to break down fat and reduce circumference of the abdomen (FDA 510(k) K192224). Morpheus8 is cleared for procedures that need coagulation or contraction of soft tissue (FDA 510(k) K231790). Avéli is cleared to reduce the appearance of cellulite on the buttocks and thighs of adult women (FDA 510(k) K221336). A tummy tuck removes excess skin and fat and, in most cases, repairs weakened or separated abdominal muscles (ASPS).

The first question to settle at a consultation is whether the main concern is fat, muscle, loose skin, cellulite, or excess skin. ASPS states that people with loose skin or poor tone may not be suitable candidates for cryolipolysis (ASPS).

Three developments matter for anyone considering body contouring now. Weight loss on GLP-1 medications includes some lean mass: in a SURMOUNT-1 substudy, about 25% of the weight lost on tirzepatide was lean mass, the same share as with placebo (Look et al., Diabetes, Obesity and Metabolism, 2025). Published rates of paradoxical adipose hyperplasia after cryolipolysis are higher than the first published estimate (Mah et al., Aesthetic Surgery Journal Open Forum, 2025). And the FDA has issued safety communications on Renuvion/J-Plasma (FDA) and on RF microneedling (FDA).

Mechanism

How non-invasive fat reduction works

The devices use cold, heat, or heat combined with muscle stimulation.

Cold (cryolipolysis). CoolSculpting Elite cools the treated area to a target temperature down to -11 °C (FDA 510(k) K233732). The injured fat cells are eliminated by the body over four to six months (ASPS).

Laser. SculpSure uses 1060 nm laser energy (FDA 510(k) K182741).

Radiofrequency. truSculpt heats tissue with radiofrequency energy; in its FDA submission, the applicator kept skin-surface temperature at 40 to 45 °C (FDA 510(k) K223110).

Radiofrequency plus muscle stimulation. Emsculpt Neo combines radiofrequency heating, with a therapy temperature of 40 to 43 °C in its FDA submission, with muscle stimulation (FDA 510(k) K192224).

ASPS reports an average fat reduction of about 20 percent in a cryolipolysis-treated area (ASPS). None of these treatments is a weight-loss method, and ASPS states that none replace liposuction (ASPS). CoolSculpting and SculpSure body-area clearances are for people with a BMI of 30 or less (FDA 510(k) K233732) (FDA 510(k) K182741).

Fat Devices

Fat reduction devices compared

CoolSculpting Elite — cryolipolysis

CoolSculpting Elite is FDA-cleared for cold-assisted lipolysis of the upper arm, bra fat, back fat, banana roll, thigh, abdomen and flank in people with a BMI of 30 or less, and of the submental and submandibular areas (under the chin and jaw) in people with a BMI up to 46.2 (FDA 510(k) K233732). ASPS describes an hour-long treatment, an average fat reduction of about 20 percent, and a risk of surface irregularities and asymmetry (ASPS). People with cryoglobulinemia, cold urticaria or paroxysmal cold hemoglobinuria should not have cryolipolysis (ASPS).

Paradoxical adipose hyperplasia (PAH) is a firm, enlarged fat area that develops in a treated spot instead of shrinking. Published rates vary:

• 0.0051%, in the first published report (Jalian et al., JAMA Dermatology, 2014)
• 0.47% (2 in 422 treatments) in one practice, which the authors described as 100 times the manufacturer’s reported incidence (Singh et al., Lasers in Surgery and Medicine, 2015)
• 0.05% to 0.39% across 8 Canadian centers and 8,658 treatment cycles; rates fell by over 75% after newer device models were introduced (Nikolis and Enright, Aesthetic Surgery Journal, 2021)
• 0.22% pooled across 28 studies and 13,078 patients, with low-certainty evidence (Mah et al., Aesthetic Surgery Journal Open Forum, 2025)
• About 1 in 3,000 treatments (0.033%), as reported by the manufacturer (Allergan Aesthetics)

ASPS states PAH is three times more likely in men than in women and is seen more often in people of Hispanic or Latino descent (ASPS); the 2025 meta-analysis found no statistically significant difference by sex (Mah et al., 2025). The 2014 report found no evidence that PAH resolves on its own (Jalian et al., 2014). In a 2018 case series of 11 patients, 7 were treated surgically (six with liposuction, one with liposuction and abdominoplasty), with treatment delayed until the area softened, normally 6 to 9 months after cryolipolysis; three of the liposuction patients needed a second procedure (Kelly et al., Plastic and Reconstructive Surgery, 2018). Ask your provider to explain PAH before you consent.

SculpSure — 1060 nm laser

SculpSure is FDA-cleared for non-invasive lipolysis of the abdomen, flanks, back and thighs in people with a BMI of 30 or less, and of the submental area in people with a BMI of 49 or less (FDA 510(k) K182741). In a single-arm study of a 1060 nm diode laser on the abdomen, one 25-minute treatment produced an 8.55% ultrasound-measured fat reduction at 12 weeks in 29 patients (Kislevitz et al., Aesthetic Surgery Journal, 2021).

truSculpt — radiofrequency

truSculpt is FDA-cleared, at its 2 MHz setting with the 40 cm² handpiece, for non-invasive lipolysis and circumference reduction of the abdomen (FDA 510(k) K223110).

Kybella — deoxycholic acid injection

Kybella is FDA-approved to improve the appearance of moderate to severe fullness from fat under the chin in adults (Kybella prescribing information). A treatment is up to 50 small injections, and up to 6 treatments may be given at least 1 month apart (Kybella prescribing information). It was studied in two placebo-controlled trials, with 513 patients treated with Kybella and 506 with placebo (Kybella prescribing information).

Use outside the chin area is not approved. The label states that Kybella is not approved for fat outside the submental region and that such use is not recommended. Serious reactions have been reported after use outside the chin area, including blurred or reduced vision with use near the eyes, and muscle or nerve injury (Kybella prescribing information). If a provider offers Kybella for another area, ask them to explain this.

In the trials, marginal mandibular nerve injury, which causes an uneven smile, occurred in 4% of Kybella-treated patients; all cases resolved without treatment (range 1 to 298 days, median 44 days). Difficulty swallowing occurred in 2% (Kybella prescribing information). The label also lists injection-site ulceration, necrosis, nodules, masses and infection (Kybella prescribing information).

This site does not publish a Houston price range for any of these treatments.

Muscle

Muscle toning: Emsculpt Neo and HIFEM

Emsculpt Neo is FDA-cleared for non-invasive lipolysis and circumference reduction of the abdomen (FDA 510(k) K192224). Its clearance study enrolled 42 people with a BMI of 35 or less. At three months it reported a 3.2 cm average reduction in abdominal circumference and a 29.8% average fat reduction on ultrasound. It was a single-arm study with no control group (FDA 510(k) K192224). BMI of 35 or less was a study entry criterion; it is not part of the cleared indication.

An earlier MRI study of the original Emsculpt (muscle stimulation without radiofrequency) in 22 patients reported, two months after four treatments, an 18.6% reduction in fat thickness, a 15.4% increase in rectus abdominis thickness and a 10.4% reduction in abdominal muscle separation (Kinney and Lozanova, Lasers in Surgery and Medicine, 2019).

A 2023 systematic review found 15 clinical studies of Emsculpt and Emsculpt Neo, only two of them on Emsculpt Neo. For the abdomen, mean reductions were 5.5 mm in fat thickness, with a 2 mm increase in muscle thickness and 3.0 mm improvement in muscle separation; two studies reported marginal or no benefit, and no study reported weight change (Kohan et al., Aesthetic Plastic Surgery, 2023).

Skin

Skin tightening and minimally invasive body contouring

Energy devices heat tissue so it contracts. They do not remove skin. Excess skin is removed surgically, for example with a tummy tuck (ASPS).

Morpheus8 — fractional radiofrequency microneedling

Morpheus8 delivers radiofrequency energy into the skin through an array of pins, and is FDA-cleared for dermatologic procedures that need coagulation or contraction of soft tissue or hemostasis (FDA 510(k) K231790). On October 15, 2025, the FDA issued a safety communication on RF microneedling, stating it is aware of reports of burns, scarring, fat loss, disfigurement and nerve damage, some requiring surgical repair or medical treatment (FDA).

BodyTite — radiofrequency-assisted liposuction

The FDA 510(k) database has no record under the name BodyTite. Ask the provider for the device’s 510(k) number and its cleared use.

Renuvion / J-Plasma — helium plasma with radiofrequency

In March 2022, the FDA warned against using Renuvion/J-Plasma for dermal resurfacing and skin contraction; at that time, the device had not been determined to be safe or effective for any aesthetic skin procedure. The FDA updated that communication on May 10, 2023, after later, narrower clearances (FDA):

• The Renuvion Dermal Handpiece is cleared for moderate to severe wrinkles in Fitzpatrick skin types I to III (FDA).
• The Renuvion APR Handpiece is cleared to improve lax skin of the neck and under the chin, and for coagulation of subcutaneous tissue after liposuction for body contouring (FDA 510(k) K230272).

Ask whether your treatment area falls within one of these cleared uses.

Cellulite

Cellulite treatments

Avéli. Avéli is a handheld instrument inserted through a small incision that releases the fibrous bands (septa) beneath cellulite dimples (FDA 510(k) K221336). It is FDA-cleared for long-term reduction in the appearance of cellulite on the buttocks and thighs of adult women, based on data showing benefits through one year. In the pivotal study, 74 women had a single treatment. The study met its primary goal, a mean improvement of more than 1 point on the Cellulite Severity Scale at 3 months, and results held at 6 and 12 months. The most common side effects were bruising (86.8%), tenderness (51.5%), pain (38.2%), firmness (36.8%) and numbness (17.6%) (FDA 510(k) K221336).

truSculpt massage device. It is FDA-cleared for a temporary reduction in the appearance of cellulite (FDA 510(k) K223110).

Qwo. Endo announced on December 6, 2022, that it would stop producing and selling Qwo, an injectable cellulite treatment, citing concerns about bruising and possible prolonged skin discoloration (Endo International, SEC filing).

ASPS states that liposuction is not an effective treatment for cellulite (ASPS).

GLP-1

Body contouring after GLP-1 weight loss

Weight loss on GLP-1 medications includes fat and some lean mass. In a SURMOUNT-1 substudy of 160 participants, those on tirzepatide lost 21.3% of body weight, 33.9% of fat mass and 10.9% of lean mass over 72 weeks; about 25% of the weight lost was lean mass, the same share as with placebo (Look et al., Diabetes, Obesity and Metabolism, 2025).

After large weight loss, the main question is how much loose skin remains:

• ASPS states that people with loose skin or poor tone may not be suitable candidates for cryolipolysis (ASPS).
• Energy devices such as Morpheus8 are cleared for soft-tissue coagulation or contraction (FDA 510(k) K231790), but they do not remove skin.
• ASPS states that skin that is soft and thin from weight loss will not reshape as well after liposuction, and more surgery may be needed to remove extra skin (ASPS).
• A tummy tuck removes excess skin and fat; ASPS advises postponing it if you plan further substantial weight loss (ASPS).

If you take a GLP-1 medication, tell the provider before any procedure, and ask whether it changes the plan.

Surgical Decision

When to consider surgical options

A consultation exam decides this. The main factors are loose skin, muscle separation, and weight:

• Liposuction surgically removes excess fat from specific areas. ASPS states that it works for people of normal weight who have some extra fat, that firm, elastic skin gives better results, and that it is not a treatment for obesity or a substitute for diet and exercise (ASPS).
• Tummy tuck (abdominoplasty) removes excess skin and fat and, in most cases, repairs weakened or separated abdominal muscles. It does not remove stretch marks and is not a substitute for weight loss. ASPS advises postponing it if you plan substantial weight loss or a future pregnancy (ASPS).
• Non-surgical fat reduction treats a specific fat bulge; ASPS states that none of these treatments replace liposuction (ASPS).

For surgery, ask the surgeon about board certification and check their Texas license on the Texas Medical Board’s Look Up a License page.

What to Expect

Consultation, treatment, recovery

Consultation. Expect questions about your medical history, including GLP-1 medications, pregnancy or breastfeeding, cold-related conditions (for cryolipolysis), and swallowing problems or bleeding problems (for Kybella) (ASPS) (Kybella prescribing information). The provider should examine whether the concern is fat, muscle, loose skin or cellulite.

Treatment and recovery. The timeline below uses the figures published for each treatment. Ask the provider for the plan and follow-up dates for your treatment.

1. Day of treatment

   Cryolipolysis: about an hour per treatment, with no activity restrictions afterward (ASPS). Kybella: up to 50 small injections under the chin (Kybella prescribing information). Avéli: a single treatment through a small incision (FDA 510(k) K221336).

2. First weeks

   Cryolipolysis: some patients feel sore, as after a workout (ASPS). Kybella: swelling, bruising, pain and numbness are common (Kybella prescribing information). Avéli: 73.5% of study patients returned to normal activities within a week; bruising lasted a median of 27 days (FDA 510(k) K221336).

3. Months 1–3

   Kybella: further treatments, if needed, at least 1 month apart (Kybella prescribing information). Emsculpt Neo: the clearance study measured results 1, 2 and 3 months after the last treatment (FDA 510(k) K192224). Avéli: the study's primary result was assessed at 3 months (FDA 510(k) K221336).

4. Months 4–6

   Cryolipolysis: treated fat cells are eliminated over four to six months (ASPS). If a treated area grows firmer and larger instead of shrinking, ask the provider to check for paradoxical adipose hyperplasia (Jalian et al., 2014).

5. One year

   Avéli: the pivotal study showed results through one year (FDA 510(k) K221336).

Houston Pricing

Houston pricing

This site does not publish a Houston price range for body contouring. Prices depend on the device, the number of areas, and the number of sessions. Ask for the total cost in writing, including any required packages, follow-up visits, and the policy for touch-ups or complications.

Combinations

How body contouring combines with other treatments

Treatments are often combined because they act on different things: fat, muscle, or skin. Ask the provider why each treatment is in the plan, the order and spacing, and what each one is FDA-cleared for. Related pages: RF microneedling, dermal fillers, and wellness and HRT.

Texas Law

How to choose a provider in Houston

Texas rules. The Texas Medical Board’s rules for delegated non-surgical medical cosmetic procedures are in 22 TAC Chapter 169, Subchapter E, effective January 9, 2025 (Texas Medical Board). They require:

• Before a delegated procedure, a physician, or a PA or APRN acting under the physician’s delegation, must establish a practitioner-patient relationship with the patient (often called a good faith exam) (22 TAC §169.26).
• A physician, PA or APRN must either be onsite during the procedure or be immediately available for emergency consultation if there is an adverse outcome (22 TAC §169.26).
• The delegation requires a written order that identifies the delegating physician and includes patient screening criteria, a description of appropriate care, and procedures for complications and emergencies (22 TAC §169.27). The person performing the procedure must also sign and date a written protocol (22 TAC §169.26).
• The delegating physician’s name and Texas license number must be posted in each public area and treatment room (22 TAC §169.28).

Questions to ask:

• Who is the delegating physician, and who performs the procedure?
• Is the device a genuine, current model from the manufacturer? In one multicenter study, PAH rates fell by over 75% after newer CoolSculpting models were introduced (Nikolis and Enright, 2021).
• Is my treatment area within the device’s FDA-cleared use?
• For CoolSculpting, how do you explain the risk of PAH, and how is it treated if it happens?
• What fat reduction should I expect, and how will you measure it? ASPS reports about 20 percent on average for cryolipolysis (ASPS).
• What is the total cost, and what is your policy for revisions and complications?

Credential checks:

• Texas Medical Board license: Look Up a License page
• Registered nurse license: Texas Board of Nursing license verification

Areas

Areas treated

• Abdomen and flanks: CoolSculpting, SculpSure (FDA 510(k) K233732) (FDA 510(k) K182741); abdomen only for Emsculpt Neo and truSculpt (FDA 510(k) K192224) (FDA 510(k) K223110).
• Thighs and banana roll: CoolSculpting (thigh, banana roll), SculpSure (thighs) (FDA 510(k) K233732) (FDA 510(k) K182741).
• Upper arms: CoolSculpting (FDA 510(k) K233732).
• Bra fat and back: CoolSculpting (bra fat, back fat), SculpSure (back) (FDA 510(k) K233732) (FDA 510(k) K182741).
• Under the chin: Kybella (Kybella prescribing information), CoolSculpting, SculpSure (FDA 510(k) K233732) (FDA 510(k) K182741), Renuvion APR for lax skin (FDA 510(k) K230272).
• Buttocks and thighs (cellulite): Avéli (FDA 510(k) K221336).